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Abstract
Background: 8-Isoprostane (8-IP) is a marker of lipid peroxidation. Elevated concentrations have been reported in
BAL fluid and exhaled breath condensate (EBC) in sarcoidosis (S). To validate the prognostic value of this marker
we tested whether: 1. high initial EBC 8-IP predispose to more severe disease; 2. low initial concentrations increase
a chance of early remission; 3. remissions are connected with the decrease of EBC 8-IP.
Methods: 40 patients (S) have been examined initially (V1) and after 8.5 ± 0.5 months (V2). EBC 8-IP concentrations
were measured by ELISA. Chest X-ray, lung function test, serum ACE and Ca
2+ concentrations, 24 hrs Ca
2+loss,
abdominal ultrasonography, symptoms evaluation were performed.
Results: We confirmed higher concentrations of 8-IP in EBC of patients with sarcoidosis (p = 0.001). Relative risk
(RR) of persistence of disease at V2 when initial 8-IP was above 20 pg/mL was 1.04, and the frequency distributions
estimated by c
2 test were not significantly different. A chance (RR) of early complete remission when V1 8-IP was
below DL, was 3.33 (p = 0.04 by c
2 test). A significant decrease of 8-IP at V2 was observed only in patients who
received treatment (p = 0.03), but not in those with spontaneous remission.
Conclusions: We come to the conclusion, that low initial 8-IP may be a positive prognostic factor. A decrease of
8-IP in treated patients reflects a non-specific effect of treatment and is not related to mere regression of disease.
Background
In more than 90% of patients suffering from sarcoidosis
lung parenchyma and intrathoracic lymphnodes are
involved. Lymphocytic inflammation with predominance
of CD4+ cells and granuloma formation are the typical
features of this disease. Remissions, usually spontaneous,
are frequent, and in many patients the disease disap-
pears within 6-12 months. Only about 5% of patients
experience a progression towards lung fibrosis [1].
Today, one of most important unresolved questions is,
which patients would benefit from treatment and what
criteria or markers should be used for qualification [2].
Oxidative stress plays a causative role in idiopathic
pulmonary fibrosis (IPF), a disease characterized by
severe lung destruction and unresponsiveness to treat-
ment [3]. Although alveolar inflammatory cells release
high concentrations of superoxide anion in active sarcoi-
dosis [4], secondary markers of oxidative stress, such as
lipid peroxidation products or oxidized methionine are
not elevated, contrary to IPF [5]. These observations
established the opinion, that oxidative stress is not a
crucial element in the pathogenesis of sarcoidosis. How-
ever, as only a minority of patients are in danger of irre-
versible lung fibrosis, it can not be excluded that
oxidative stress with subsequent peroxidation of mem-
brane lipids is also important in the pathogenesis of
lung fibrosis in this selected group of sarcoid patients.
8-Isoprostane (8-IP) is a marker of oxidative stress. It
is a prostaglandin-F2a isomer, produced in vivo by free
radical-catalyzed peroxidation of arachidonic acid [6].
Elevated concentrations of 8-IP in BALF [7] and exhaled
breath condensate (EBC) [8,9] in patients suffering from
sarcoidosis have been reported. In our previous paper
we reported, that higher concentrations of 8-IP in EBC
are found in a more extensive disease (radiological stage
III), that raises hopes, that this marker could have a
prognostic value [9].
T h e r e f o r ew eu n d e r t o o kt h i ss t u d yt oe v a l u a t et h e
clinical value of EBC 8-IP in sarcoid patients, followed
over a period of 6-12 months. We were especially inter-
ested, whether high initial EBC 8-IP concentrations
* Correspondence: piotrow@toya.net.pl
Department of Pneumology and Allergy, Medical University of Lodz, Poland
Piotrowski et al. BMC Pulmonary Medicine 2010, 10:23
http://www.biomedcentral.com/1471-2466/10/23
© 2010 Piotrowski et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.predispose to more severe disease, low initial concentra-
tions increase a chance of early remission, and whether
remissions are connected with the decrease of EBC 8-IP
concentrations.
Methods
Study group
40 caucasian patients (23 women, age 39 ± 11) with sar-
coidosis were included. In all patients the diagnosis was
proved by histo-pathological examination, except those
with the stage I/II disease with acute onset and typical
radiological and BAL features [1]. Four patients had been
treated in the past, but all were treatment-naïve for at
least 12 months at the time of initial evaluation. They
were non-smokers, non-atopic, and had no significant
co-morbidities. Respiratory infection in the last 4 weeks
was an exclusion criterion. Extrapulmonary sarcoidosis
was suspected or proven in 14 patients (enlarged spleen
in USG - 7, skin changes other than erythema nodosum -
6, impaired liver function tests - 2, positive liver biopsy -
1, enlarged abdominal lymphnodes - 1, facial nerve
palsy - 1). Although extrapulmonary involvement was
not a subject of our study, regression of extrapulmonary
signs present at V1 was a condition to qualify a patient as
healthy at V2 (complete remission). Characteristics of the
study group is presented in Table 1. Four patients from
the present study group participated in the study pub-
lished previously (10%) [9].
Control group
34 healthy never smokers (19 women, age 45 ± 10),
members of a hospital staff, free of respiratory infection
in the last 4 weeks.
Ethics
The study was approved by Ethical Committee at Medi-
cal University of Lodz (consent N° RNN/99/08/KE) and
all patients signed informed consent.
Exhaled breath condensate collection
EBC was collected using a condensing device (Ecosc-
reen, Jaeger, Germany). Patients were asked to breath
out spontaneously through a mouthpiece equipped with
a saliva trap for 10 min. The respiratory rate ranged
from 15 to 20 breaths/min. All subjects wore a nose-clip
a n dr i n s e dt h e i rm o u t h sw i t hd i s t i l l e dw a t e rj u s tb e f o r e
and after the 7
th min of the condensing process, in
order to reduce nasal contamination. Samples were
stored at -80°C until measurements. The collection of
EBC was performed following available recommenda-
tions [10].
Measurement of 8-isoprostane
Concentrations of 8-isoprostane in EBC were measured
b yas p e c i f i ce n z y m ei m m o n o a s s a y( E I A )k i t( C a y m a n
Chemical, Ann Arbour, MI) as previously described [9].
The detection limit was 5 pg/ml. Levels of measured
mediator below the detection limit were arbitrarily
assumed to be half of the detection limit value. All sam-
ples were measured in duplicate. The intra-assay repro-
ducibility (coefficient of variation, CV) calculated from all
measurements was 13.2%. The inter-assay reproducibility
was estimated on the basis of repeated measurements in
17 control subjects (samples taken over a 4 week inter-
val). The CV was 19.0%. In 2 subjects (11.8%) the one-
grade change between 8-IP concentration was found
between ranges (from <5 to 5-20 pg/mL).
Other procedures at V1 and V2
All patients had postero-anterior and lateral chest X-ray
(CXR) and high resolution computed tomography
(HRCT). Lung function tests were performed according
to ERS/ATS standards [11,12]. FEV1,F V C ,F E V 1/FVC
and lung diffusion capacity, corrected for haemoglobin
(DLCOc) was measured. Bronchoscopy with bronchoal-
veolar lavage (BAL) was performed only at V1, accord-
ing to British Thoracic Society Guidelines [13]. BAL was
collected and worked out as described previously [9].
Blood was collected for serum angiotensin converting
Table 1 Radiological stages, lung function tests
parameters, frequency of patients with Löfgren
syndrome, abnormal laboratory results, % of patients on
treatment and disease duration in patients at initial
evaluation (V1) and follow-up (V2) visits
Feature Visit 1 Visit 2
Stage I 23 (57.5%) 13 (-10 with CR)
Stage II 9 (22.5%) 8 (-1 with CR)
Stage III 8 (20%) 8 (no CR)
FEV1 (% predicted) 92.6 ± 3.2 93.8 ± 3.1
FVC (% predicted) 97.9 ± 3.0 99.7 ± 2.9
FEV1/FVC (%) 0.81 ± 0.02 0.80 ± 0.02
DLCOc (% predicted) 87.3 ± 3.4 87.7 ± 3.7
LS present and past 20 (50%) -
LS present 15 (37.5%) 0
SACE > 68 IU/L 11 (27.5%) 5 (12.5%)
S-Ca
2+ > 2.62 mmol/L 1 (2.5%) 2 (5%)
U-Ca
2+ > 7.5 mmol/24 h 3 (7.5%) 5 (12.5%)
CRP > 5 mg/L 15 (37.5%) 5 (12.5%)
On treatment 0 8 (20%)
T from first symptoms to V1
(weeks, median: 25-75 percentile)
10 [4-60] -
CR – complete remission, DLCOc – diffusion capacity for CO corrected for
hemoglobin, FEV1 #8211; forced expiratory volume in 1
st second of expiration,
FVC – forced vital capacity, LS – Löfgren syndrome, S – serum, SACE – serum
angiotensin converting enzyme, T – time, U – urine.
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lected for calcium loss.
Definitions of disease progression and activity
For the purpose of this study, to define evolution of
t h ed i s e a s ea tv i s i t2w eu s e das i m p l es c o r i n gs y s t e m
(Table 2). According to the number of points at the final
visit, the patient was put into one of the following groups:
Complete remission - complete regression of radiolo-
gical findings and no symptoms, laboratory results nor-
mal, no signs of other extrapulmonary involvement
(score at V2 = 0).
Partial remission - radiological improvement but
chest X-ray still abnormal, or complete regression of
radiological findings but at least one laboratory abnorm-
ality, or any general or respiratory symptom consistent
with clinical picture of sarcoidosis present, or persis-
tence of any other signs of pulmonary and extrapulmon-
ary sarcoidosis (score at V2 ≥ 1, but decreased ≥ 2
points compared to V1).
Stabilization - no change in radiological picture and
lung function tests results, no progression in clinical
symptoms and new laboratory abnormalities, no new
extrapulmonary manifestations (score at V2 ± 1 point
compared to V1).
Progression - worsening of radiological findings and/
or lung function tests results, new pulmonary, general
and extrapulmonary symptoms (score at V2 increased ≥
2p o i n t s ) .T h i si so n l yt h e o r e t i c a l ,a st h e r ew e r en o
patients with progression in our study group. For
statistical analysis only two groups were considered:
complete remission (CR) and no complete remission
(no-CR, including partial remission and stabilization).
Statistical analysis
Data were shown as mean ± standard error of means
(SEM), with exception of age (mean± standard deviation).
Kolmogorow-Smirnoff test was used to assess normality.
Median with 25 and 75 percentile was provided, for not
normally distributed data. Unpaired T-test (for normally
distributed data) or Mann-Whitney test (for non-para-
metric data) was used to compare sarcoidosis with the
controls. Paired T-test was used for calculation of differ-
ences between V1 and V2 results of EBC 8-IP in treated
patients and untreated patients with spontaneous remis-
sion. When more than 2 groups were compared with,
one-way ANOVA and Bonferroni post-test (for data with
Gaussian distribution) or Kruskall-Wallis followed by
Dunn’s Multiple Comparison Test (for data without nor-
mal distribution) were used. Relative risk (RR) as a ratio
of expected to unexpected risks was calculated. The dif-
ferences in frequency distribution between subgroups
(remission vs no remission when 8-IP <5 or >20 pg/mL)
were estimated by c
2 and Fischer tests. Spearman test
was applied to assess correlations. The p value ≤ 0.05 was
assumed as statistically significant.
Results
EBC 8-IP concentrations were higher in sarcoidosis
(median; 25-75 percentile): 8.50; 2.50-17.40 vs 2.50;
Table 2 Estimation of clinical status of sarcoidosis at follow-up visit (V2)
V2 examinations Score
Radiology (CXR) 0. normal
1. abnormal, improved to V1
2. abnormal, no change to V1
3. worse than V1
LFT
(FEV1, FVC, FEV1/FVC, DLCOc)
0. FEV1/FVC>70%, other parameters ≥ 80% predicted
1. FEV1/FVC≤ 70%, at least one of the other < 80% predicted
Laboratory (SACE, CRP, S-Ca
2+, U-Ca
2+) 0. all within NL
1. at least one out of NL
Lofgren syndrome (EN, elevated BT, arthritis, oedema) 0. absent
1. present
General symptoms (fatigue, weight loss, sweating, arthralgia, myalgia etc) 0. absent
1. present
Respiratory symptoms (cough, breathlessness, exercise intolerance etc) 0. absent
1. present
Extrapulmonary signs and symptoms 0. absent
1. present
Only patients with the sum of points at V2 = 0 were qualified as having complete remission. BT – body temperature, DLCOc – diffusion capacity for CO corrected
for hemoglobin, EN – erythema nodosum, FEV1 – forced expiratory volume in 1
st second of expiration, FVC – forced vital capacity, LFT - lung function tests, NL –
normal; limits, S – serum, SACE – serum angiotensin converting enzyme, T – time, U – urine.
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Page 3 of 72.50-3.90, p = 0.001. In 14 out of 40 patients (35%) and
in 26 out of 34 healthy controls (76%) 8-isoprostane
concentrations were below detection limit (Figure 1).
Concentrations were the highest in stage III (p = 0.03 vs
stage I), and the proportion of readings below detection
limit were: 12/23 (52%), 1/9 (11%) and 1/8 (12.5%) in
stages I, II and III, respectively (Figure 2).
Relative risk (RR) of persistence of sarcoidosis in
6-12 months of follow-up when initial 8-IP was above
20 pg/mL was 1.04 (95%CI = 0.21-4.19, p = 0.94). The
chance of early remission (RR) when 8-IP was below
detection limit was 3.33 (95%CI = 1.20-5.78, p = 0.03).
We found a significant relationship between low 8-IP
concentrations (below detection limit) and frequency of
complete remission (p = 0.04). See contingency table for
detailed results (Table 3).
A significant decrease of 8-isoprostane concentration
at V2 was observed only in patients, who received sys-
temic steroids (p = 0.02) (Figure 3), but was not
observed in other patients, especially those, who experi-
enced spontaneous complete remission. When treated
patients were excluded from analysis, there were no sig-
nificant differences in V1:V2 ratio between prognostic
groups (CR vs no-CR).
There was no significant correlation between 8-IP or
V1:V2 8-IP ratio and BAL cells, laboratory parameters
of activity or duration of disease.
Table 4 shows data of BAL cellularity, lung function
test parameters, laboratory parameters, time from onset
of disease to V1 and frequency of Löfgren syndrome in
subgroups divided according to radiological stage.
Discussion
This is the first study analyzing possible prognostic
value of exhaled breath 8-isoprostanes in sarcoidosis.
We confirmed earlier results, showing higher EBC 8-
isoprostane concentrations, especially in patients with
more advanced pulmonary changes. In this follow-up
study (albeit short) we have also shown, that low 8-
isoprostane (rather than high levels) may describe future
prognosis, literally that patients with values below
Figure 1 Comparison of exhaled breath condensate (EBC)
8-isoprostane (8-IP) concentrations in healthy controls and all
sarcoidosis patients.
Figure 2 Comparison of exhaled breath condensate (EBC)
8-isoprostane (8-IP) concentrations in sarcoidosis patients
divided according to radiological stages. There was a significant
difference between stages estimated by Kruskal-Wallis test
(p = 0.03). The Dunn’s Multiple Comparison post-test showed the
significant difference between stage I and III (p < 0.05). There were
no differences between stage I and II and stage II and III (p > 0.05).
Table 3 Contingency table
EBC 8-IP [pg/mL]
< 5 5-20 > 20 Total
CR (+) No of patients 7 2 2 11
% with CR 63.6 18.2 18.2 100
% with EBC 8-IP level 50.0 10.5 28.6 27.5
c
2 p = 0.04
CR (-) No of patients 7 17 5 29
% with CR 24.1 58.6 17.2 100
% with EBC 8-IP level 50.0 89.5 71.4 72.5
c
2 NS
Total No of patients 14 19 7 40
% with CR 35.0 47.5 17.5 100
% with EBC 8-IP level 100 100 100 100
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in a short period of time.
Sarcoidosis is usually a self-limiting disease, which
lasts 12-36 months in 50% of patients, in the majority of
cases disappears with no or minimal consequences
within 5 years, at the latest [1]. Remissions within
6 months are not uncommon, especially in stage I and
with those with Löfgren syndrome (LS) [1]. In our find-
ings complete early remissions occurred in 11 out of all
(40) sarcoid patients (10 were diagnosed as stage I, 1 as
stage II, 8 presented LS). Therefore, we decided to ana-
lyze the rate of early remissions (6-12 months) in the
context of 8-IP concentrations in EBC.
Do high initial EBC 8-isoprostane concentrations
predispose to more severe disease
Initial concentrations of 8-IP were significantly higher in
patients with more advanced disease (radiological stage
3). Undetectable levels of EBC 8-IP were much less fre-
quent in stage II and III compared to controls and
patients within stage I. However, patients with the high-
est levels (above the highest concentration in a control
group) do not show significantly increased risk of dis-
ease persistence after few months of observation. Due to
Figure 3 Changes of exhaled breath condensate (EBC)
8-isoprostane (8-IP) concentrations between visit 1 – first
assessment (V1) and visit 2 – follow up (V2) in treated patients
and those who experienced spontaneous complete remission.
Table 4 BAL cytological pattern, lung function tests parameters, laboratory results, % of patients on treatment and
time from first symptoms to visit 1 in sarcoidosis patients divided according to radiological stage
Stage I Stage II Stage III Difference
BAL lymphocytes (%) 29.6 ± 3.5 34.9 ± 7.3 32.8 ± 7.0 NS
BAL lymphocytes (× 10
4/mL) 5.03 ± 1.08 8.5 ± 2.7 10.98 ± 4.15 NS
BAL neutrophils (%) 1 ± 0.33
(1) [0-1]
1.13 ± 0.4
(1) [0-2]
0.33 ± 0.21
(0) [0-5]
NS
BAL neutrophils
(× 10
4/mL)
0.15 ± 0.06 0.22 ± 0.08 0.23 ± 0.22 NS
BAL eosinophils (%) 1.17 ± 0.25
(1) [0.5-1.5]
0.75 ± 0.25
(1) [0-1]
0.72 ± 0.32
(1) [0-5]
NS
BAL eosinophils
(× 10
4/mL)
0.14 ± 0.03 0.16 ± 0.25 0.72 ± 0.32 p ≤ 0.01: I vs III
p ≤ 0.05: II vs III
FEV1 (% predicted) 99.4 ± 3.5 81.1 ± 7.5 87.8 ± 7.0 p ≤ 0.05: I vs II
FVC (% predicted) 104.7 ± 3.5 84.8 ± 7.0 94.9 ± 4.0 p ≤ 0.05: I vs II
FEV1/FVC (%) 0.83 ± 0.02 0.78 ± 0.04 0.77 ± 0.04 NS
DLCOc (% predicted) 96.8 ± 4.4 77.4 ± 6.0 77.1 ± 6.3 p ≤ 0.05: I vs II&III
SACE (IU/L) 65.8 ± 8.6 98.8 ± 30.3 45.8 ± 12.8 NS
S-Ca
2+(mmol/L) 2.46 ± 0.02 2.44 ± 0.08 2.50 ± 0.02 NS
U-Ca
2+(mmol/24 h) 5.25 ± 0.48 5.15 ± 0.94 4.52 ± 0.83 NS
CRP (mg/L) 7.30 ± 2.27
(5.0)
[1.5-7.1]
19.85 ± 8.77
(9.4)
[4.6-25.3]
4.40 ± 1.71
(2.5)
[0.7-6.7]
NS
T from onset to V1
(weeks)
38 ± 25
(8) [4-24]
107 ± 50
(8) [4-238]
149 ± 55
(88) [18-289]
p ≤ 0.05: I vs III
LS 15/23 5/9 0/8 -
DLCOc – diffusion capacity for CO corrected for hemoglobin, FEV1 – forced expiratory volume in 1
st second of expiration, FVC – forced vital capacity,
LS – Löfgren syndrome, S – serum, SACE – serum angiotensin converting enzyme, T – time, U – urine, V1 – visit 1.
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of these results should be taken into consideration. We
know, that many patients experience complete remission
later than after a year. In this study these patients could
not have been identified. It means, that final results
should be evaluated in the long-term follow-up study
after at least a 2 year period, or even later.
Do low initial concentrations increase a chance of early
remission?
Our results show, that the chance of early remission is
> 3 times higher in patients, who had concentrations of
8-IP in EBC below the detection limit. It is intriguing
however, that some of these patients show-up with ele-
vated EBC 8-IP after several months, regardless of the
absence of clinical signs of the disease. This again, will
deserve a long-term study, whether these patients are in
danger of future relapse.
The value of our results was diminished by the fact that
many sarcoid patients have low levels of EBC 8-IP. On
the other hand, there is a substantial overlapping of sar-
coidosis and control group results, therefore it is impossi-
ble to set up a clear cut-off level for “abnormal” results.
In addition, although a large percentage of patients with
stage I do recover early, we know from other studies and
from everyday practice, that some patients experience
relapses, usually within 2 years after remission. This can
be evaluated in a long-term follow-up study.
Do remissions are connected with the decrease of
EBC 8-isoprostane concentrations?
We found, that only patients who received treatment
between V1 and V2 (and who were on treatment at V2)
have significantly reduced EBC 8-IP. In all, partial
remissions were observed. This observation is especially
striking in contrast with the lack of such an effect on
the rest of patients, especially in those who experienced
complete remission (in 5 out of 11 an increase was
recorded). It suggests only unspecific role of systemic
steroids, unrelated to the mere regression of granuloma-
tous inflammation. Antczak et al. found decreased EBC
8-IP concentrations in inhaled steroid-treated patients
with aspirin-sensitive and aspirin-insensitive asthma,
comparing to steroid-naïve patients [14]. Other authors
do not confirm that inhaled steroids may decrease EBC
8-IP [15], however administration of oral steroids due to
asthma exacerbation in children resulted in a significant
decrease of EBC 8-IP [16].
There is no data in the literature on the possible influ-
ence of steroid treatment on EBC 8-IP in sarcoidosis
and other interstitial lung disease.
On the basis of our results it is difficult to explain
why some patients with clinical remission have high
concentrations of 8-IP in exhaled breath at final evalua-
tion. The influence of other clinical states should be
considered. Although infection and allergy were exclu-
sion critera, we were not able to exclude subclinical
states, which could have influenced the measurements.
In some patients bronchial hyperreactivity may evolve
[17], which would give another possible explanation for
these outstanding results. Finally, we can not exclude,
that in some of these subjects the disease is still active
or will result in relapses.
Oxidative stress in the pathogenesis of sarcoidosis
Our results provide an argument for the possible role of
oxidative stress and lipid peroxidation in sarcoidosis.
Production of superoxide anion by BAL cells is
increased proportionately to the grade of lymphocytic
inflammation [18]. Oxidative stress may be involved
even in the very early stages of granuloma formation, as
oxidants may stimulate macrophages to the production
of TNF-a and other cytokines indispensable for granu-
loma formation. TNF-a may be detectable in EBC, how-
ever the concentrations were not elevated in sarcoidosis
[19]. Although, we have not measured TNF-a in our
patient’s EBC, such data would be interesting in the
context of the possible application of anti-TNF agents in
the treatment of refractory sarcoidosis [20]. Elevated 8-
IP concentrations in EBC may be related to the destruc-
tion of cellular membranes, but further studies are
required to evaluate whether patients with high EBC
8-IP have a higher risk of lung fibrosis.
Conclusions
This short-term follow-up study does not provide an evi-
dence for negative prognostic value of high levels of EBC
8-IP. A long-term follow up study, involving more
numerous and clinically heterogenous group of patients
is necessary for conclusive evaluation. However, our data
shows, that low concentrations of 8-IP in EBC may pre-
dispose to early remission. Complete remissions are not
connected with a consistent decrease of EBC 8-IP. Only
in patients treated with steroids, regardless the remission
was achieved, the decrease of EBC 8-IP was noticed.
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